Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lixte Biotechnology Holdings Inc.

4.34
-0.4300-9.01%
Post-market: 4.33-0.0100-0.23%17:55 EDT
Volume:286.32K
Turnover:1.32M
Market Cap:19.80M
PE:-3.40
High:4.97
Open:4.77
Low:4.28
Close:4.77
52wk High:6.26
52wk Low:0.6400
Shares:4.56M
Float Shares:2.87M
Volume Ratio:3.11
T/O Rate:9.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2749
EPS(LYR):-1.5943
ROE:-213.21%
ROA:-99.79%
PB:30.39
PE(LYR):-2.72

Loading ...

Lixte Biotechnology Holdings Inc. Announces Leadership Reshuffle with Geordan Pursglove as CEO and Bas van der Baan as Chief Scientific Officer

Reuters
·
Sep 16

Lixte Biotechnology Invests $2.6M in Cryptocurrencies

TIPRANKS
·
Sep 12

Lixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum for $2.6M

TIPRANKS
·
Sep 11

Lixte Biotechnology Holdings Inc - Purchases 10.5 Bitcoin and 300 Ethereum for $2.6 Mln

THOMSON REUTERS
·
Sep 11

Lixte Biotechnology Holdings Inc. Files Initial Beneficial Ownership Statement for Director Guy Primus

Reuters
·
Sep 11

Lixte Biotechnology Holdings Inc. Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting Cancer Treatment Synergies

Reuters
·
Sep 05

Lixte Biotechnology Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Felix Lourdes

Reuters
·
Sep 05

BRIEF-Lixte Biotechnology Holdings Inc - Peter Stazzone Has Been Named Chief Financial Officer

Reuters
·
Sep 03

Lixte Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

THOMSON REUTERS
·
Sep 03

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

GlobeNewswire
·
Aug 27

24/7 Market News: Lixte Biotech Advances Precision Oncology Pipeline With Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

THOMSON REUTERS
·
Aug 14

Lixte Biotechnology Holdings Inc - Board Approves 25% Treasury Allocation to Cryptocurrencies

THOMSON REUTERS
·
Aug 13

Lixte Biotech Hldgs Q2 EPS $(0.29) Up From $(0.45) YoY

Benzinga
·
Aug 07

Lixte Biotechnology Holdings Inc. Announces Board Changes: Jason Sawyer and Dr. Michael Holloway Appointed, Dr. Stephen Forman and Dr. Yun Yen Transition to Scientific Advisory Committee

Reuters
·
Jul 22

Lixte Biotechnology Unveils Promising Study Results: LB-100 Shows Enhanced Immunotherapy Response in Ovarian and Colorectal Cancer Trials

Reuters
·
Jul 11

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

GlobeNewswire
·
Jul 09

Top Premarket Decliners

MT Newswires Live
·
Jul 07

Lixte Biotechnology Closes Higher After Share Sale to Regain Nasdaq Compliance

Dow Jones
·
Jul 04

Dow Jumps Over 200 Points; US Nonfarm Payrolls Beat Estimates

Benzinga
·
Jul 03

Lixte Biotechnology Closes $5 Million Private Placement

MT Newswires Live
·
Jul 03